Quantitative T2′ imaging in patients with clinically isolated syndrome

Acta Neurologica Scandinavica

Volumn 126, Issue 5, 2012, Pages 357-363

  Reitz, L Y ^a   Inglese, M ^b   Fiehler, J ^a   Finsterbusch, J ^a   Holst, B ^a   Heesen, C ^a   Martin, R ^a,c   Schippling, S ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Clinically isolated syndrome; magnetic resonance imaging; Metabolic changes; Normal appearing white matter; Quantitative imaging; T2

Indexed keywords

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; FEMALE; GRAY MATTER; HUMAN; IMAGE PROCESSING; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; WHITE MATTER; BRAIN; COMPUTER ASSISTED DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; BRAIN; DEMYELINATING DISEASES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84867098514     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01635.x     Document Type: Article

References (35)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005;4:341-8.
3. Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000;21:1034-8.
4. Fooladi M, Alam NR, Harirchyan MH et al. Prognostic value of brain tissue pathological changes in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis using magnetization transfer ratio (MTR). Conf Proc IEEE Eng Med Biol Soc 2007;2007:2031-3.
5. Traboulsee A, Dehmeshki J, Brex PA et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 2002;59:126-8.
6. Gallo A, Rovaris M, Riva R et al. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 2005;62:803-8.
7. Roelcke U, Kappos L, Lechner-Scott J et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48:1566-71.
8. An H, Lin W. Quantitative measurements of cerebral blood oxygen saturation using magnetic resonance imaging. J Cereb Blood Flow Metab 2000;20:1225-36.
9. Geisler BS, Brandhoff F, Fiehler J et al. Blood-oxygen-level-dependent MRI allows metabolic description of tissue at risk in acute stroke patients. Stroke 2006;37:1778-84.
10. Holst B, Siemonsen S, Finsterbusch J et al. T2′ imaging indicates decreased tissue metabolism in frontal white matter of MS patients. Mult Scler 2009;15:701-7.
11. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-45.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
13. Gold SM, Heesen C, Schulz H et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001;7:119-30.
14. Van AUDM, Audoin B, Le FURY et al. Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS: a MRSI study. J Neurol 2007;254:914-23.
15. Rovaris M, Judica E, Ceccarelli A et al. A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. J Neurol 2008;255:1209-14.
16. Henry RG, Shieh M, Amirbekian B, Chung S, Okuda DT, Pelletier D. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009;282:61-6.
17. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236-44.
18. Dalton CM, Chard DT, Davies GR et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-7.
19. Audoin B, Zaaraoui W, Reuter F et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:690-5.
20. Ramsaransing G, Maurits N, Zwanikken C, De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult Scler 2001;7:345-7.
21. Burman J, Raininko R, Fagius J. Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurol Scand 2011;123:207-10.
22. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17.
23. Costelloe L, Thompson A, Walsh C, Tubridy N, Hutchinson M. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 2008;79:1245-8.
24. Brex PA, Ciccarelli O, O'riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64.
25. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-71.
26. Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998;8:228-34.
27. Blinkenberg M, Jensen CV, Holm S, Paulson OB, Sorensen PS. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology 1999;53:149-53.
28. Il'ves AG, Prakhova LN, Kataeva GV et al. [Clinical and radiological (PET, MRI) correlations depending on disease progression in patients with multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2006;Spec No3:81-6.
29. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003;13:554-73.
30. Fernando KT, Mclean MA, Chard DT et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127:1361-9.
31. Fiehler J, Geisler B, Siemonsen S et al. [Visual rating of T2′-blood-oxygen-level-dependent magnetic resonance imaging in acute stroke patients-a pilot study]. Rofo 2007;179:17-20.
32. Siemonsen S, Fitting T, Thomalla G et al. T2′ imaging predicts infarct growth beyond the acute diffusion-weighted imaging lesion in acute stroke. Radiology 2008;248:979-86.
33. Lunde Larsen LS, Larsson HB, Frederiksen JL. The value of conventional high-field MRI in MS in the light of the McDonald criteria: a literature review. Acta Neurol Scand 2010;122:149-58.
34. Paulesu E, Perani D, Fazio F et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage 1996;4:87-96.
35. Feuillet L, Reuter F, Audoin B et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007;13:124-7.